Pulse Biosciences Reports Business Updates and First Quarter 2023 Financial Results
Business Updates
- Announced the appointment of Gansevoort “Gan” Dunnington, MD, as Chief Medical Officer, Cardiac Surgery; Dr. Dunnington is a key opinion leading cardiothoracic surgeon pioneering novel less-invasive technologies to improve the lives of patients with atrial fibrillation.
- Completed a pre-submission meeting with the FDA to review the regulatory requirements for the Company’s nsPFA surgical ablation clamp as part of the standard Q-submission process; expect continued engagement with FDA to finalize the regulatory path for the device.
- Continued development across several preclinical studies for the Company’s nsPFA cardiac ablation catheter device to support a first-in-human feasibility study.
-
Entered into a
$65 million -
Announced decision to redeem all outstanding warrants from the Company’s June 2022 Rights Offering; the exercise of warrants in 2023 represents an opportunity to raise up to an additional
$15.0 million
“In the first quarter we advanced our preclinical and regulatory objectives for our two novel nsPFA devices, the surgical ablation clamp and cardiac ablation catheter. Our preclinical evidence continues to demonstrate differentiated benefits of nsPFA that we believe can advance the treatment of atrial fibrillation,” said Kevin Danahy, Chief Executive Officer of Pulse Biosciences. “We are excited to expand our leadership team with the appointment of our Chief Medical Officer, Dr. Gan Dunnington. He has been actively involved with the preclinical studies of our nsPFA surgical ablation clamp and shares our enthusiasm about the potential of the technology. His continued contributions will be extremely valuable as we advance clinical, regulatory, and potential commercialization of the device.”
First Quarter 2023 Results
Total GAAP cost and expenses, representing cost of revenues, research and development, sales and marketing, and general and administrative expenses, for the three months ended March 31, 2023, were
GAAP net loss for the three months ended March 31, 2023, was
Cash and cash equivalents totaled
Reconciliations of GAAP to non-GAAP cost and expenses and net loss have been provided in the tables following the financial statements in this press release. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.”
Webcast and Conference Call Information
Pulse Biosciences’ management will host a conference call today, May 11, 2023, beginning at 1:30pm PT. Investors interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers. A live and recorded webcast of the event will be available at https://investors.pulsebiosciences.com/.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The Company is actively pursuing the development of its nsPFA technology for use in electrophysiology and the treatment of atrial fibrillation. Visit pulsebiosciences.com to learn more.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in
Non-GAAP Financial Measures
In this press release, in order to supplement the Company’s condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles, or GAAP, management has disclosed certain non-GAAP financial measures for the statement of operations. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results in order to supplement investors’ and other readers’ understanding and assessment of the Company’s financial performance. Company management uses these measurements as aids in monitoring the Company’s ongoing financial performance from quarter to quarter, and year to year, on a regular basis and for financial and operational decision-making. Non-GAAP adjustments include stock-based compensation, depreciation and amortization and restructuring charges. From time to time in the future, there may be other items that the Company may exclude if the Company believes that doing so is consistent with the goal of providing useful information to management and investors. The Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure. Investors are cautioned that there are a number of limitations associated with the use of non-GAAP financial measures as analytical tools. Investors are encouraged to review these reconciliations, and not to rely on any single financial measure to evaluate the Company’s business.
Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies, which could reduce the usefulness of the Company’s non-GAAP financial measures as tools for comparison. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP. Non-GAAP financial measures in this earnings release exclude the following:
Non-cash expenses for stock-based compensation. The Company has excluded the effect of stock-based compensation expenses in calculating the Company’s non-GAAP cost and expenses and net loss measures. Although stock-based compensation is a key incentive offered to employees, the Company continues to evaluate its business performance excluding stock-based compensation expenses. The Company records stock-based compensation expense related to grants of performance and time-based options. Depending upon the size, timing and terms of the grants, as well as the probability of achievement of performance-based awards, this expense may vary significantly but will recur in future periods. The Company believes that excluding stock-based compensation better allows for comparisons from period to period.
Depreciation and amortization. The Company has excluded depreciation and amortization expense in calculating its non-GAAP cost and expenses and net loss measures. Depreciation and amortization are non-cash charges to current operations.
Restructuring charges. The Company has excluded restructuring charges in calculating its non-GAAP cost and expenses and net loss measures. Restructuring programs involve discrete initiatives designed to improve operating efficiencies and include employee termination, contract termination, and other exit costs associated with the restructuring program. The Company believes that excluding discrete restructuring charges allows for better comparisons from period to period.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the effectiveness of the Company’s nsPFA technology and CellFX System to non-thermally clear cells while sparing adjacent non-cellular tissue, statements concerning the Company’s expected product development efforts, such as advancement of its cardiac clamp through the appropriate FDA regulatory path and possible initiation of a first-in-human safety feasibility study of its nsPFA cardiac ablation catheter system, statements concerning the Company’s future regulatory strategies and possible government clearances and approvals, statements concerning customer adoption and future use of the CellFX System to address a range of conditions such as atrial fibrillation, statements about the Company’s redemption of warrants and other future financing opportunities and operating expenses, and Pulse Biosciences’ expectations, whether stated or implied, regarding whether the Company’s nsPFA technology will become a disruptive treatment option for treating cardiac arrhythmias and whether future clinical studies will show the CellFX System is safe and effective to treat atrial fibrillation or any other medical condition, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
PULSE BIOSCIENCES, INC. |
||||||||
Condensed Consolidated Balance Sheets |
||||||||
(In thousands, except per share amounts) |
||||||||
(Unaudited) |
||||||||
March 31, |
December 31, |
|||||||
2023 |
2022 |
|||||||
ASSETS |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ |
54,098 |
|
$ |
61,139 |
|
||
Prepaid expenses and other current assets |
849 |
|
1,008 |
|
||||
Total current assets |
|
54,947 |
|
62,147 |
|
|||
Property and equipment, net |
1,865 |
|
1,961 |
|
||||
Intangible assets, net |
2,384 |
|
2,551 |
|
||||
Goodwill |
2,791 |
|
2,791 |
|
||||
Right-of-use assets |
7,869 |
|
8,062 |
|
||||
Other assets |
365 |
|
365 |
|
||||
Total assets |
$ |
70,221 |
|
$ |
77,877 |
|
||
|
|
|||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||
Current liabilities: |
||||||||
Accounts payable |
$ |
2,160 |
|
$ |
1,573 |
|
||
Accrued expenses |
3,091 |
|
2,595 |
|
||||
Deferred revenue |
4 |
|
— |
|
||||
Lease liability, current |
935 |
|
896 |
|
||||
Related party note payable, current |
801 |
|
917 |
|
||||
Total current liabilities |
|
6,991 |
|
5,981 |
|
|||
Lease liability, less current |
8,898 |
|
9,144 |
|
||||
Related party note payable, less current |
|
65,000 |
|
65,000 |
|
|||
Total liabilities |
|
80,889 |
|
80,125 |
|
|||
Stockholders’ equity: |
||||||||
Preferred stock, authorized – 50,000 shares; no shares issued and outstanding |
— |
|
— |
|
||||
Common stock, authorized – 500,000 shares; issued and outstanding – 37,593 shares and 37,235 shares at March 31, 2023 and December 31, 2022, respectively |
37 |
|
37 |
|
||||
Additional paid-in capital |
293,801 |
|
292,420 |
|
||||
Accumulated other comprehensive income (loss) |
— |
|
— |
|
||||
Accumulated deficit |
(304,506 |
) |
(294,705 |
) |
||||
Total stockholders’ deficit |
|
(10,668 |
) |
(2,248 |
) |
|||
Total liabilities and stockholders’ deficit |
$ |
70,221 |
|
$ |
77,877 |
|
||
PULSE BIOSCIENCES, INC. |
||||||||
Condensed Consolidated Statements of Operations and Comprehensive Loss |
||||||||
(In thousands, except per share amounts) |
||||||||
(Unaudited) |
||||||||
Three-Month Periods Ended |
||||||||
March 31, |
||||||||
2023* |
2022 |
|||||||
Revenues: |
||||||||
Product revenues |
$ |
— |
|
$ |
444 |
|
||
Total revenues |
— |
|
444 |
|
||||
Cost and expenses: |
||||||||
Cost of revenues |
— |
|
909 |
|
||||
Research and development |
5,829 |
|
6,769 |
|
||||
Sales and marketing |
— |
|
5,541 |
|
||||
General and administrative |
3,733 |
|
4,498 |
|
||||
Total cost and expenses |
|
9,562 |
|
17,717 |
|
|||
Loss from operations |
(9,562 |
) |
(17,273 |
) |
||||
Other income (expense): |
||||||||
Interest income (expense), net |
|
(239 |
) |
— |
|
|||
Total other income (expense) |
(239 |
) |
— |
|
||||
Net loss |
|
(9,801 |
) |
(17,273 |
) |
|||
Other comprehensive gain (loss): |
||||||||
Unrealized gain (loss) on available-for-sale securities |
— |
|
— |
|
||||
Comprehensive loss |
$ |
(9,801 |
) |
$ |
(17,273 |
) |
||
Net loss per share: |
||||||||
Basic and diluted net loss per share |
$ |
(0.26 |
) |
$ |
(0.58 |
) |
||
Weighted average shares used to compute net loss per common share — basic and diluted |
|
37,390 |
|
29,745 |
|
|||
Three-Month Periods Ended |
||||||||
March 31, |
||||||||
Stock Based Compensation Expense: |
2023* |
2022 |
||||||
Cost of revenues |
$ |
— |
$ |
90 |
||||
Research and development |
258 |
457 |
||||||
Sales and marketing |
— |
454 |
||||||
General and administrative |
638 |
1,006 |
||||||
Total stock-based compensation expense |
$ |
896 |
$ |
2,007 |
||||
*For the three month period ended March 31, 2023, the Company reclassified certain expenses as a result of the shift in focus from dermatology to cardiology. The Company is no longer selling the CellFX system into the dermatology market, and is therefore no longer incurring Cost of Revenues. Expenses previously included in Cost of Revenues are now recorded as a part of Research and Development, and expenses previously included in Sales and Marketing are now recorded as a part of General and Administrative. Going forward, the Company will evaluate the classification of expenses as research and development or general and administrative in accordance with ASC Topic 730, Research and Development.
Reconciliation of GAAP to Non-GAAP Financial Measures |
|||||||
The following table presents the reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures: |
|||||||
(In thousands) |
|||||||
(Unaudited) |
|||||||
Three-Month Periods Ended |
|||||||
March 31, |
|||||||
2023 |
|
2022 |
|||||
Reconciliation of GAAP to non-GAAP Cost of revenues: |
|||||||
GAAP Cost of revenues |
$ |
— |
|
$ |
909 |
|
|
Less: Stock-based compensation expense |
— |
|
(90 |
) |
|||
Less: Depreciation and amortization |
— |
|
(5 |
) |
|||
Less: Restructuring |
— |
|
(19 |
) |
|||
Non-GAAP Cost of revenues |
$ |
— |
|
$ |
795 |
|
|
Reconciliation of GAAP to non-GAAP Research and development: |
|||||||
GAAP Research and development |
$ |
5,829 |
|
$ |
6,769 |
|
|
Less: Stock-based compensation expense |
(258 |
) |
(457 |
) |
|||
Less: Depreciation and amortization |
(57 |
) |
(59 |
) |
|||
Less: Restructuring |
(38 |
) |
(127 |
) |
|||
Non-GAAP Research and development |
$ |
5,476 |
|
$ |
6,126 |
|
|
Reconciliation of GAAP to non-GAAP Sales and marketing: |
|||||||
GAAP Sales and marketing |
$ |
— |
|
$ |
5,541 |
|
|
Less: Stock-based compensation expense |
— |
|
(454 |
) |
|||
Less: Depreciation and amortization |
— |
|
(13 |
) |
|||
Less: Restructuring |
— |
|
(546 |
) |
|||
Non-GAAP Sales and marketing |
$ |
— |
|
$ |
4,528 |
|
|
Reconciliation of GAAP to non-GAAP General and administrative: |
|||||||
GAAP General and administrative |
$ |
3,733 |
|
$ |
4,498 |
|
|
Less: Stock-based compensation expense |
(638 |
) |
(1,006 |
) |
|||
Less: Depreciation and amortization |
(244 |
) |
(249 |
) |
|||
Less: Restructuring |
(12 |
) |
(41 |
) |
|||
Non-GAAP General and administrative |
$ |
2,839 |
|
$ |
3,202 |
|
|
Reconciliation of GAAP to non-GAAP Cost and expenses: |
|||||||
GAAP Cost and expenses |
$ |
9,562 |
|
$ |
17,717 |
|
|
Less: Stock-based compensation expense |
(896 |
) |
(2,007 |
) |
|||
Less: Depreciation and amortization |
(301 |
) |
(326 |
) |
|||
Less: Restructuring |
(50 |
) |
(733 |
) |
|||
Non-GAAP Cost and expenses |
$ |
8,315 |
|
$ |
14,651 |
|
|
Reconciliation of GAAP to non-GAAP Net loss: |
|||||||
GAAP Net loss |
$ |
(9,801 |
) |
$ |
(17,273 |
) |
|
Add: Stock-based compensation expense |
896 |
|
2,007 |
|
|||
Add: Depreciation and amortization |
301 |
|
326 |
|
|||
Add: Restructuring |
50 |
|
733 |
|
|||
Non-GAAP Net loss |
$ |
(8,554 |
) |
$ |
(14,207 |
) |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005798/en/
Investor Contacts:
Pulse Biosciences
Kevin Danahy, President and CEO
510.241.1077
IR@pulsebiosciences.com
or
Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com
Source: Pulse Biosciences, Inc.
